Daiichi Sankyo

Daiichi Sankyo
2 Hilton Court
Parsippany, NJ 07054
Phone: (973) 944-2600Website: https://dsi.com/homeCareers: careers.dsi.comPatient Assistance Program: dsi.com/patient-assistance-programs

Latest news

Quizartinib NDA Review for Patients with Newly Diagnosed FLT3-ITD Positive AML Extended by FDA
21 April 2023
Quizartinib Granted Priority Review in the U.S. for Patients with Newly Diagnosed FLT3-ITD Positive Acute Myeloid Leukemia
24 October 2022
Quizartinib Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy in Patients with Newly Diagnosed FLT3-ITD Positive Acute Myeloid Leukemia
11 June 2022
Injectafer (ferric carboxymaltose injection) Receives FDA Approval for the Treatment of Pediatric Patients with Iron Deficiency Anemia
16 December 2021
Quizartinib Added to Chemotherapy Demonstrates Superior Overall Survival Compared to Chemotherapy Alone in Adult Patients with Newly Diagnosed FLT3-ITD Positive AML
18 November 2021
Injectafer (ferric carboxymaltose injection) Receives FDA Approval for Single Dose Option for the Treatment of Adult Patients with Iron Deficiency Anemia
6 May 2021
FDA Approves Turalio (pexidartinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumors (TGCT) in Adults
2 August 2019
Daiichi Sankyo Provides Update on FDA Review of Quizartinib for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
21 June 2019
Daiichi Sankyo Announces Outcome of FDA Oncologic Drugs Advisory Committee Meeting to Review FLT3 Inhibitor Quizartinib for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
14 May 2019
FDA Oncologic Drugs Advisory Committee Votes in Favor of Daiichi Sankyo’s Pexidartinib for the Treatment of Select Patients with TGCT, a Rare, Debilitating Tumor
14 May 2019

Drugs Associated with Daiichi Sankyo

Daiichi Sankyo manufactures, markets and/or distributes more than 13 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.

Brand/Generic Name	Reviews	Rating
Azor Generic name: amlodipine/olmesartan Drug class: angiotensin II inhibitors with calcium channel blockers	56 reviews	8.5 / 10
Benicar Generic name: olmesartan Drug class: angiotensin receptor blockers	98 reviews	7.3 / 10
Benicar HCT Generic name: hydrochlorothiazide/olmesartan Drug class: angiotensin II inhibitors with thiazides	25 reviews	6.5 / 10
Effient Generic name: prasugrel Drug class: platelet aggregation inhibitors	20 reviews	7.0 / 10
Enhertu Generic name: fam-trastuzumab deruxtecan Drug class: HER2 inhibitors	3 reviews	5.0 / 10
Evoxac Generic name: cevimeline Drug class: cholinergic agonists	18 reviews	7.2 / 10
Injectafer Generic name: ferric carboxymaltose Drug class: iron products	6 reviews	7.0 / 10
Movantik Generic name: naloxegol Drug class: peripheral opioid receptor antagonists	232 reviews	4.8 / 10
Savaysa Generic name: edoxaban Drug class: factor Xa inhibitors	2 reviews	1.0 / 10
Tribenzor Generic name: amlodipine/hydrochlorothiazide/olmesartan Drug class: miscellaneous antihypertensive combinations	19 reviews	7.5 / 10
Turalio Generic name: pexidartinib Drug class: multikinase inhibitors
Welchol Generic name: colesevelam Drug class: bile acid sequestrants	39 reviews	8.0 / 10
Zelboraf Generic name: vemurafenib Drug class: multikinase inhibitors	4 reviews	6.2 / 10
For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective).

Discontinued Drugs

Brand/Generic Name	Reviews	Rating
MorphaBond ER Generic name: morphine Drug class: Opioids (narcotic analgesics)	6 reviews	2.5 / 10
For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective).